All News
Excellent irAE summary by Ryan Sullivan -judicious use of steroids, High doses when needed, low dose when possible. Pre-existing AID not a contradiction to checkpoint inhibitor Tx! @RheumNow @LCalabreseDO @cappelliMD @lexmeara #ACR19 #cleclinicrheum https://t.co/TOTXQzxXhp
Cassandra Calabrese CCalabreseDO ( View Tweet)
Do you co-manage your PsO/PsA patients with dermatology? #ACR19 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
So glad that our clinical study from @RBNHSFT looking at the outcome measures in Axial Spondyloarthritis eg. BASDAI, ASDAS, CRP, BASFI and the impact on response to treatment was delivered today as an oral presentation with good feedback at #ACR19 #axialspondyloarthritis
Dr. Antoni Chan synovialjoints ( View Tweet)
Continued Ixekizumab was superior to PBO in maintaining MDA in biologic-naïve PsA pts who achieved sustained MDA on initial IXE treatment. A vast majority of pts who lost MDA after IXE withdrawal regained MDA with IXE re-treatment presented by @DrLauraCoates #ACR19 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Relapsing Polychondritis: a 4th more worrying phenotype
#ACR19 @rheumnow 4M086 https://t.co/4EAgBb07cV
Dr Irwin Lim _connectedcare ( View Tweet)
Relapsing Polychondritis: 3 more common clinical phenotypes
#ACR19 @rheumnow 4M086 https://t.co/aqNQMYCao2
Dr Irwin Lim _connectedcare ( View Tweet)
Relapsing Polychondritis: speaker’s recommendations
#ACR19 @rheumnow 4M086 https://t.co/G2TIOfTGiW
Dr Irwin Lim _connectedcare ( View Tweet)
What’s your first line therapy for AS? Write below if you use something else!
@RheumNow #ACR19
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow What is your primary pharmacotherapy for inflammatory-type erosive hand OA?
#ACR19 @RheumNow Plenary II ABST1759/1760
David Liew drdavidliew ( View Tweet)
FRAME study results: Romo increases MBBF on the Ec and Cn surfaces which stimulates bone formation during first 2 months of tx. https://t.co/qmbyt8w75Q #abs1874 #ACR19 @RheumNow https://t.co/FQIIU8kcsp
Dr. Rachel Tate uptoTate ( View Tweet)
#acrbest @rheumnow #acr19 abstr#1901
VERY IMPT STUDY: 16,490 offspring of moms w/Rheum Dz: 105 on nonTNFi biologic or TOFA:
NO ⬆️in utero SIE . Only 2 cases of SIE- 1 w/TOFA &1 w/ABT.
Risk for SIE in utero
For healthy 1.6%
For TNFi 2.3%
For nonTNFi + TOFA 2.1%
k dao KDAO2011 ( View Tweet)
SLE has high work disability. Interestingly work disability was not high in some organ systems such as renal but mild GN or CRF may not be symptomatic. Fibromyalgia, low education, low SED and older age increase work disability ACR219 @RheumNow abstr 1578 https://t.co/DdHgluRPIV
Janet Pope Janetbirdope ( View Tweet)
DAPS study results suggest ALN use following DMAb cessation and BMD monitoring of patients transitioning from DMAb to ALN. https://t.co/xQHnevYyed abs #1875 #ACR19 @RheumNow https://t.co/DR13Cn6EYD
Dr. Rachel Tate uptoTate ( View Tweet)
Abstr#1898 #acr19 #acrbest @rheumnow Danish registry prospective RA pregnancy and offspring outcome n= 816 children born to parent w/RA- they performed a little worse in math grades 2,4,6, 8 compared to peers regardless of maternal seropositivity. No influence by paternal RA.
k dao KDAO2011 ( View Tweet)
Study by Malik et al shows Magnetic Resonance Enterography (MRE) as a screening tool to detect Sacroilitis (SI) in Crohns Disease patients. Presence of SI on MRE in CD was found in 17% of patients. With back pain, this can lead to earlier diagnosis AxSpA #ACR19 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
OP related fracture risk projected to increase to 33% by 2030. Medicare cohort from 2010- 2014 data review suggestions worsening fracture management. https://t.co/anG80uMjEV abs#1872 #ACR19 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#acr19 @RheumNow abstr#1899 #acrbest
71 preg pts
sFlt-1, PlGF and VEGF possible biomarkers to disting b/t active SLE Nephritis During Pregnancy and Preeclampsia
VEGF ⬆️ in LN
PIGF ⬇️ in preeclamp
sFlt-1 ⬆️ in preeclamp
sFlt-1: PlGF ratio is much higher in preeclampsia
k dao KDAO2011 ( View Tweet)
#ACR19 @rheumnow abs1339 Risk of ImmunoRx related toxicity in pts w/pre-existing AI disease+ malignancy &Rx w/ ICIs comparable to pts w/out preexist AI Dx: IrAEs 32%pts w/only 9% severe,grade 3 irAEs, total 41% toxicity of any grade. most common tox dermatitis 18%& colitis 14%
Olga Petryna DrPetryna ( View Tweet)
#acr19 @rheumnow Great debate
Who won? Dr Saag (62% yes votes)
But Dr Humphrey NO-anabolic stance as first line for GIO make sense for many patients; antiresorptives do work for GIO and cost per fracture prevented is so much less
k dao KDAO2011 ( View Tweet)
#acr19 @rheumnow Great debate
Dr Saag rebuttal PRO anabolic 1st line rationale for GIO:
- Dr Humphrey herself wrote in 2014 and 2018 that teriparatide can be considered as 1st line for GIO https://t.co/GjMrs0YYdj
k dao KDAO2011 ( View Tweet)